---
layout: default
title: Pimozide
description: "Pimozide çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 126
evidence_level: L3
indication_count: 10
---

# Pimozide

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Pimozide è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Pimozide å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Pimozide ç‚ºæ²»ç™‚ç²¾ç¥ç—…çš„å¤šå·´èƒºå—é«”é˜»æ–·åŠ‘ï¼ŒTxGNN é æ¸¬å¯èƒ½å°æ‹”æ¯›ç—‡ã€èºé¬±ç—‡åŠ ADHD ç­‰ç²¾ç¥ç–¾ç—…æœ‰æ½›åœ¨ç™‚æ•ˆï¼Œä¸¦æœ‰å¤šç¯‡æ–‡ç»æ”¯æŒã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥å“å­¸å | Pimozide (åŒ¹è«éœ) |
| DrugBank ID | DB01100 |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | ç²¾ç¥ç—…ã€ç²¾ç¥åˆ†è£‚ç—‡ã€å¹»è¦ºã€å¦„æƒ³ |
| TxGNN é æ¸¬æ–°é©æ‡‰ç—‡ | trichotillomaniaã€manic bipolar affective disorderã€Tourette syndromeã€insomnia (disease)ã€major affective disorderã€attention deficit-hyperactivity disorderã€faciodigitogenital syndromeã€Malan overgrowth syndromeã€attention deficit hyperactivity disorder, inattentive typeã€agoraphobia |
| å°ç£è¨±å¯è­‰æ•¸ | 11 å¼µ |
| æœ€é«˜è­‰æ“šç­‰ç´š | L3 (è§€å¯Ÿæ€§ç ”ç©¶) |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. trichotillomania</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">100.00%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Pimozide ä½œç‚ºé¸æ“‡æ€§å¤šå·´èƒº D2 å—é«”é˜»æ–·åŠ‘ï¼Œå…¶é æ¸¬çš„æ–°é©æ‡‰ç—‡åœ¨æ©Ÿè½‰ä¸Šå…·æœ‰åˆç†æ€§ï¼š</p>

<ol>
<li><strong>æ‹”æ¯›ç—‡ (Trichotillomania)</strong>ï¼šå±¬æ–¼å¼·è¿«ç—‡è­œç³»éšœç¤™ï¼Œå¤šå·´èƒºç³»çµ±åœ¨è¡å‹•æ§åˆ¶ä¸­æ‰®æ¼”é‡è¦è§’è‰²</li>
<li><strong>èºé¬±ç—‡ (Manic bipolar disorder)</strong>ï¼šèºç—‡èˆ‡å¤šå·´èƒºéåº¦æ´»åŒ–æœ‰é—œï¼Œé˜»æ–· D2 å—é«”å¯æ¸›ç·©èºç—‡ç—‡ç‹€</li>
<li><strong>æ³¨æ„åŠ›ä¸è¶³éå‹•ç—‡ (ADHD)</strong>ï¼šå¤šå·´èƒºç³»çµ±ç•°å¸¸æ˜¯ ADHD æ ¸å¿ƒç—…ç†æ©Ÿè½‰ä¹‹ä¸€</li>
</ol>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr>
<th>é æ¸¬é©æ‡‰ç—‡</th>
<th>è‡¨åºŠè©¦é©—æ•¸</th>
<th>ä»£è¡¨æ€§è©¦é©—</th>
</tr>
</thead>
<tbody>
<tr>
<td>é‡é¬±ç—‡</td>
<td>2</td>
<td>NCT00374244: Pimozide å¢å¼· Clozapine æ²»ç™‚é›£æ²»æ€§ç²¾ç¥åˆ†è£‚ç—‡</td>
</tr>
<tr>
<td>æ‹”æ¯›ç—‡</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>èºé¬±ç—‡</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>ADHD</td>
<td>0</td>
<td>-</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>### æ‹”æ¯›ç—‡ (Trichotillomania)</p>
<p><strong>è­‰æ“šç­‰ç´šï¼šL3 (è§€å¯Ÿæ€§ç ”ç©¶/ç—…ä¾‹å ±å‘Š)</strong></p>

<table>
<thead>
<tr>
<th>PMID</th>
<th>æ¨™é¡Œ</th>
<th>å¹´ä»½</th>
<th>é‡é»ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td>15554735</td>
<td>Pimozide in dermatologic practice: a comprehensive review</td>
<td>2004</td>
<td>Pimozide è¢«ç™¼ç¾å°æ‹”æ¯›ç—‡æœ‰æ•ˆï¼Œæ˜¯çš®è†šç§‘ç²¾ç¥ç–¾ç—…çš„é¸æ“‡ä¹‹ä¸€</td>
</tr>
<tr>
<td>1532960</td>
<td>Low-dose pimozide augmentation of SRI in trichotillomania</td>
<td>1992</td>
<td>ä½åŠ‘é‡ Pimozide å¯å¢å¼· SSRI æ²»ç™‚æ‹”æ¯›ç—‡çš„æ•ˆæœ</td>
</tr>
<tr>
<td>10497682</td>
<td>Under-diagnosed psychiatric syndrome: Trichotillomania</td>
<td>1999</td>
<td>æåŠ Pimozide å’Œ Haloperidol å°æ‹”æ¯›ç—‡æœ‰ä¸åŒç¨‹åº¦ç™‚æ•ˆ</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. manic bipolar affective disorder</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17017818/" target="_blank">17017818</a></td><td>2006</td><td>Article</td><td>The Journal of clini</td><td>Efficacy of typical and atypical antipsychotics for primary ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7093595/" target="_blank">7093595</a></td><td>1982</td><td>Article</td><td>The British journal </td><td>Plasma prolactin and growth hormone levels in manic patients...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/970489/" target="_blank">970489</a></td><td>1976</td><td>Article</td><td>The American journal</td><td>A dopaminergic mechanism in mania.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2497949/" target="_blank">2497949</a></td><td>1989</td><td>Article</td><td>Canadian journal of </td><td>Tourette disorder and bipolar symptomatology in childhood an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11249804/" target="_blank">11249804</a></td><td>2000</td><td>Article</td><td>Bipolar disorders</td><td>Onset of action of antipsychotics in the treatment of mania.</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. insomnia (disease)</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ3 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1112170/" target="_blank">1112170</a></td><td>1975</td><td>Article</td><td>Diseases of the nerv</td><td>Pimozide in chronic schizophrenic outpatients.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2590789/" target="_blank">2590789</a></td><td>1989</td><td>Article</td><td>The British journal </td><td>Psychotic illness following termination of pregnancy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4679652/" target="_blank">4679652</a></td><td>1972</td><td>Article</td><td>Acta psychiatrica Be</td><td>Clinical observations on the use of primozide in the treatme...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. major affective disorder</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.96%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ2 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02600741" target="_blank">NCT02600741</a></td><td>N/A</td><td>COMPLETED</td><td>296</td><td>A 12-Month Randomized, Open-Label Study of Caregiver Psycho-education and Skills...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00374244" target="_blank">NCT00374244</a></td><td>PHASE2</td><td>COMPLETED</td><td>28</td><td>Efficacy of Pimozide Augmentation for Clozapine Partial Response</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ11 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17017818/" target="_blank">17017818</a></td><td>2006</td><td>Article</td><td>The Journal of clini</td><td>Efficacy of typical and atypical antipsychotics for primary ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23672254/" target="_blank">23672254</a></td><td>2013</td><td>Article</td><td>BMC gastroenterology</td><td>Psychiatric treatment considerations with direct acting anti...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12547298/" target="_blank">12547298</a></td><td>2003</td><td>Article</td><td>Journal of affective</td><td>P300 changes in major depressive disorders with and without ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14971869/" target="_blank">14971869</a></td><td>2003</td><td>Article</td><td>Annals of clinical p</td><td>Atypical antipsychotics in the treatment of delusional paras...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/829615/" target="_blank">829615</a></td><td>1975</td><td>Article</td><td>Psychiatrie, Neurolo</td><td>[Experiences in the long term use of the 24 hour effective n...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 6 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. attention deficit-hyperactivity disorder</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34757514/" target="_blank">34757514</a></td><td>2022</td><td>Article</td><td>European child &amp; ado</td><td>European clinical guidelines for Tourette syndrome and other...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36528030/" target="_blank">36528030</a></td><td>2023</td><td>Article</td><td>The Lancet. Child &amp; </td><td>Comparative efficacy, tolerability, and acceptability of pha...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12185806/" target="_blank">12185806</a></td><td>2002</td><td>Article</td><td>Neurologia i neuroch</td><td>[Tic syndrome].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32206587/" target="_blank">32206587</a></td><td>2020</td><td>Article</td><td>Translational pediat</td><td>Tourette&#x27;s disorder in children and adolescents.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7976448/" target="_blank">7976448</a></td><td>1994</td><td>Article</td><td>Acta psychiatrica Sc</td><td>Effects of pimozide on cognition in children with Tourette s...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. faciodigitogenital syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. Malan overgrowth syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.76%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. attention deficit hyperactivity disorder, inattentive type</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.72%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. agoraphobia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.71%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. benign paroxysmal torticollis of infancy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.65%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

### ä¸Šå¸‚ç‹€æ…‹
å°ç£å·²æ ¸å‡†ä¸Šå¸‚ï¼Œå…±æœ‰ 11 å¼µè¨±å¯è­‰ï¼Œç›®å‰æœ‰æ•ˆè¨±å¯è­‰ 2 å¼µã€‚

### ä»£è¡¨æ€§ç”¢å“

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | æ•ˆæœŸ |
|------------|--------|------|--------------|------|
| è¡›ç½²è—¥è£½å­—ç¬¬043118è™Ÿ | åå…¨æœé¬±éŒ 2æ¯«å…‹ | éŒ åŠ‘ | åå…¨å¯¦æ¥­è‚¡ä»½æœ‰é™å…¬å¸ | 2029/07/21 |
| è¡›ç½²è—¥è£½å­—ç¬¬044175è™Ÿ | æ´»æ½‘éŒ  | éŒ åŠ‘ | äº•ç”°åœ‹éš›é†«è—¥å» è‚¡ä»½æœ‰é™å…¬å¸ | 2030/12/20 |

### æ ¸å‡†é©æ‡‰ç—‡
ç²¾ç¥ç—…ç‹€æ…‹ã€ç²¾ç¥åˆ†è£‚ç—‡

## å®‰å…¨æ€§è€ƒé‡

### è—¥ç‰©äº¤äº’ä½œç”¨

DDInter è³‡æ–™åº«é¡¯ç¤º Pimozide èˆ‡å¤šç¨®è—¥ç‰©æœ‰äº¤äº’ä½œç”¨ï¼š

**åš´é‡äº¤äº’ä½œç”¨ (Major)**ï¼š
- Hydrocortisone
- Amphotericin B
- å¯èƒ½å»¶é•· QT é–“è·ï¼Œéœ€ç‰¹åˆ¥æ³¨æ„å¿ƒè‡Ÿå®‰å…¨æ€§

**ä¸­åº¦äº¤äº’ä½œç”¨ (Moderate)**ï¼š
- Famotidine
- Epinephrine

### æ³¨æ„äº‹é …
1. **QT å»¶é•·é¢¨éšª**ï¼šPimozide å¯å»¶é•· QT é–“è·ï¼Œç¦æ­¢èˆ‡å…¶ä»–å»¶é•· QT è—¥ç‰©ä½µç”¨
2. **CYP3A4/CYP2D6 ä»£è¬**ï¼šèˆ‡é€™äº›é…µç´ çš„æŠ‘åˆ¶åŠ‘ä½µç”¨æœƒå¢åŠ  Pimozide è¡€ä¸­æ¿ƒåº¦
3. **éŒé«”å¤–ç—‡ç‹€**ï¼šé•·æœŸä½¿ç”¨å¯èƒ½å°è‡´é²ç™¼æ€§é‹å‹•éšœç¤™




### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**è‘¡è„æŸšæ±** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©ä»£è¬ã€‚å¯èƒ½å¢åŠ è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ã€‚
- å»ºè­°ï¼šå»ºè­°é¿å…ä½µç”¨ã€‚é¿å…é£Ÿç”¨è‘¡è„æŸšæˆ–è‘¡è„æŸšæ±ã€‚

**é…’ç²¾** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©ä»£è¬ã€‚å¯èƒ½å¢åŠ è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ã€‚
- å»ºè­°ï¼šå»ºè­°é¿å…ä½µç”¨ã€‚

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰é™ä½ Pimozide è¡€ä¸­æ¿ƒåº¦ï¼Œå¯èƒ½å½±éŸ¿ç™‚æ•ˆ
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Seizures** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šç™²ç™‡ç™¼ä½œã€‚

**Hyperprolactinemia** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šAntipsychotic drugs can elevate serum prolactin concentrations, and this elevation persists during chronic administration...

**Neutropenia** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Anticholinergic Syndrome** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šè¡€å£“æ§åˆ¶ä¸è‰¯ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šè€å¹´äººã€‚

**Hyperprolactinemia** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**Parkinsonian Disorders** ğŸŸ¡ Moderate
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

**Tardive Dyskinesia** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šTardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dys...

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šPimozide is extensively metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney...

**Dementia** ğŸŸ¢ Minor
- å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Central Nervous System Diseases** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Neuroleptic Malignant Syndrome** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**ç™²ç™‡** ğŸŸ¢ Minor
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šç™²ç™‡ç™¼ä½œã€‚

**Alcoholic Intoxication** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Respiratory Insufficiency** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Neuroleptic Malignant Syndrome** ğŸŸ¢ Minor
- é¢¨éšªåŒ…æ‹¬ï¼šå¿ƒå¾‹ä¸æ•´ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Pituitary Neoplasms** ğŸŸ¢ Minor
- æ³¨æ„äº‹é …ï¼šPimozide may have a tumorigenic potential and has been shown to cause a dose-related increase in pituitary tumors in mice...

**Long QT Syndrome** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå¿ƒå¾‹ä¸æ•´ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Tics** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬åƒ¹å€¼è©•ä¼°

| é æ¸¬é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | æ–‡ç»æ”¯æŒ | è‡¨åºŠè©¦é©— | ç¸½è©• |
|------------|----------|----------|----------|------|
| æ‹”æ¯›ç—‡ | L3 | 10 ç¯‡ | 0 | ä¸­åº¦æ”¯æŒ |
| èºé¬±ç—‡ | L3 | 22 ç¯‡ | 0 | å¼·åŠ›æ”¯æŒ |
| å¤±çœ  | L3 | 3 ç¯‡ | 0 | è¼•åº¦æ”¯æŒ |
| é‡é¬±ç—‡ | L3 | 11 ç¯‡ | 2 | ä¸­åº¦æ”¯æŒ |
| ADHD | L3 | å¤šç¯‡ | 0 | ä¸­åº¦æ”¯æŒ |

### å»ºè­°
1. **èºé¬±ç—‡**ï¼šå·²æœ‰å……åˆ†æ–‡ç»æ”¯æŒ Pimozide å°èºç—‡çš„ç™‚æ•ˆï¼Œä½†éœ€æ³¨æ„ QT å»¶é•·é¢¨éšª
2. **æ‹”æ¯›ç—‡**ï¼šå¯ä½œç‚º SSRI æ²»ç™‚ç„¡æ•ˆæ™‚çš„è¼”åŠ©æ²»ç™‚é¸é …
3. ä»»ä½•æ–°é©æ‡‰ç—‡ä½¿ç”¨å‰éœ€é€²è¡Œå®Œæ•´å¿ƒé›»åœ–è©•ä¼°

---
*æœ¬ç­†è¨˜ç”± TwTxGNN ç³»çµ±è‡ªå‹•ç”¢ç”Ÿï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*
*ç”¢ç”Ÿæ—¥æœŸï¼š2026-02-11*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Gefitinib]({{ "/drugs/gefitinib/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Clomipramine]({{ "/drugs/clomipramine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Avelumab]({{ "/drugs/avelumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Sulfamethazine]({{ "/drugs/sulfamethazine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Trastuzumab Deruxtecan]({{ "/drugs/trastuzumab_deruxtecan/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Pimozideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/pimozide/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_pimozide,
  title = {Pimozideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/pimozide/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
